Comparison · NCT00855465-sae
Riociguat (Adempas, BAY63-2521)_individual Dose Titration vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Riociguat (Adempas, BAY63-2521)_individual Dose Titration vs Placebo: serious adverse events. Trial comparisons, record NCT00855465-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00855465-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.197 | 0.144 | 0.262 | wilson | |
| Risk in group 2 | 0.159 | 0.0972 | 0.25 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0374 | -0.067 | 0.128 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.24 | 0.701 | 2.18 | log | |
| Odds ratio, group 1 over group 2 | 1.29 | 0.653 | 2.56 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Riociguat (Adempas, BAY63-2521)_individual Dose Titration than on Placebo | 26.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Riociguat (Adempas, BAY63-2521)_individual Dose Titration | Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks | 34 | 173 | EG000 |
| Group 2 | Placebo | Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks | 14 | 88 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected after signing the informed consent until 2 days after end of study treatment over a period of approximately 30 days.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
- NCT number
- NCT00855465
- Phases
- PHASE3
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2014-03-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00855465?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00855465-sae